Old Web
English
Sign In
Acemap
>
authorDetail
>
Xuan Liu
Xuan Liu
Bristol-Myers Squibb
Nivolumab
Medicine
Chemotherapy
Internal medicine
Oncology
2
Papers
32
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.
2021
Journal of Clinical Oncology
Ian Chau
Yuichiro Doki
Jaffer A. Ajani
Jianming Xu
Lucjan Wyrwicz
Satoru Motoyama
Takashi Ogata
Hisato Kawakami
Chih-Hung Hsu
Antoine Adenis
Farid El Hajbi
Maria Di Bartolomeo
Maria Ignez Braghiroli
Eva Holtved
Ioannis Xynos
Xuan Liu
Ming Lei
Kaoru Kondo
Ken Kato
Yuko Kitagawa
Show All
Source
Cite
Save
Citations (11)
A randomized phase II study of cabiralizumab (cabira) + nivolumab (nivo) ± chemotherapy (chemo) in advanced pancreatic ductal adenocarcinoma (PDAC).
2019
Journal of Clinical Oncology
Andrea Wang-Gillam
Eileen Mary OReilly
Johanna C. Bendell
Zev A. Wainberg
Erkut Borazanci
Nathan Bahary
Mark H. O'Hara
Gregory L. Beatty
Shubham Pant
Deirdre Jill Cohen
Stephen Leong
Muhammad Shaalan Beg
Kenneth H. Yu
T.R. Jeffry Evans
Thomas Seufferlein
Takuji Okusaka
Penny Phillips
Xuan Liu
Serena Perna
Dung T. Le
Show All
Source
Cite
Save
Citations (21)
1